23-25 October 2024
Rockville, MD - USA
Menu
The Adolphe Quetelet Society is delighted to invite you to the
A primary goal of this meeting is to facilitate interaction between statisticians from FDA and industry, to discuss the acceptability of Bayesian methods in regulatory submissions.
This includes discussions of recent FDA programs designed to increase Bayesian content of new drug applications, including the Complex Innovative Trial Design (CID) meeting program, the Bayesian Supplemental Analysis (BSA) demonstration project, the Accelerating Rare disease Cures (ARC) program, and others.
bayes@lsacademy.com
The Adolphe Quetelet Society is an official region of the International Biometric Society (IBS). As such the society endorses the same objectives and Code of Conduct as its mother organization:
IBS Code of Conduct : The International Biometric Society (IBS) highly values professional and appropriate behavior at all times. This involves scientific and ethical integrity, as well as respectful conduct towards others regardless of gender, gender identity and expression, age, sexual orientation, disability, physical appearances, race, religion (or lack thereof) or beliefs.
Members of the IBS, as well as everyone employed on behalf of IBS or attending events organized by IBS, are expected to endorse this position and they agree to be considerate in speech and actions, to respect others, and to refrain from demeaning, discriminatory, or harassing behavior and speech, at all times.
Copyright © 2024 Bayes-Pharma